cataracts

Newly appointed business advisory board member Daniel Feller is "a pillar of the rare genetic disease community in Australia," according to Nacuity co-founder and CEO Halden Conner.

Nacuity Pharmaceuticals Expands Business Advisory Board

by | Feb 23, 2024
Newly appointed business advisory board member Daniel Feller is "a pillar of the rare genetic disease community in Australia," according to Nacuity co-founder and CEO Halden Conner.
MORE►
With $16.5M in New Funding, Fort Worth’s Nacuity Aims to Treat ‘Serious Blinding and Chronic Diseases’
by | Jun 15, 2022
Nacuity Pharmaceuticals focuses on ocular diseases caused by oxidative stress in the retina, including age-related macular degeneration, glaucoma, and diabetic retinopathy. The $16.5M funding, led by the Foundation Fighting Blindness, will help advance two Nacuity clinical trials. “This funding will help further our mission to develop a breakthrough treatment for retinitis pigmentosa and other serious blinding and chronic diseases," said Nacuity Chairman, CEO, and Co-founder Halden Conner.
MORE►
A Special Thank you to our sponsors

A collaboration of the Dallas Regional Chamber and Dallas Next, Dallas Innovates is an online news platform covering what's new + next in Dallas - Fort Worth innovation.

© Copyright 2024 | All rights reserved.

Business

Creative

Education

Impact

Invention

Startup

Our Sponsors

Our Partners